Oral Oncology, Journal Year: 2024, Volume and Issue: 161, P. 107143 - 107143
Published: Dec. 17, 2024
Language: Английский
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(2), P. 542 - 542
Published: Jan. 10, 2025
Diabetes mellitus (DM) and neurodegenerative diseases/disturbances are worldwide health problems. The most common chronic conditions diagnosed in persons 60 years older type 2 diabetes (T2DM) cognitive impairment. It was found that is a major risk for decline, dementia, Parkinson's disease (PD), Alzheimer's (AD), Huntington's (HD), amyotrophic lateral sclerosis (ALS) other disorders. Different mechanisms of associations between these diseases have been suggested. For example, it postulated an impaired intracellular insulin signaling pathway, together with hyperglycemia hyperinsulinemia, may cause pathological changes, such as dysfunction the mitochondria, oxidative stress inflammatory responses, etc. association diseases, well associations, needs further investigation. aim this review to describe mellitus, especially 1 (T1DM) selected i.e., disease, sclerosis. Suggested also described.
Language: Английский
Citations
3
Medicina, Journal Year: 2025, Volume and Issue: 61(4), P. 678 - 678
Published: April 7, 2025
Growing interest in incretin-based therapies for diabetes mellitus has led to an increased evaluation of their potential effects on cancer development. This review aims synthesize recent evidence regarding the relationship between and risk. We conducted a comprehensive literature focusing studies investigating dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists relation various malignancies. Current findings suggest that while these demonstrate benefits, including weight reduction metabolic regulation, concerns remain long-term safety profile. Notably, some indicate risk thyroid pancreatic cancers, others report protective against prostate, colorectal, breast cancers. Given complexity effects, further post-marketing surveillance are warranted. highlights need careful clinical assessment when prescribing patients who may be at cancer.
Language: Английский
Citations
0
Clinical Nutrition, Journal Year: 2024, Volume and Issue: 43(11), P. 137 - 152
Published: Oct. 1, 2024
Language: Английский
Citations
3
RSC Advances, Journal Year: 2025, Volume and Issue: 15(9), P. 7191 - 7199
Published: Jan. 1, 2025
Monotherapy in diabetes management is losing interest due to its ineffectiveness achieving optimal glycaemic control a significant proportion of diabetic patients. Therefore, combined therapy increasingly preferred by clinicians, which offers enhanced effectiveness and better safety profile for managing the condition. The present work deals with designing dual drug nanocarrier based on MCM-48 12-tungtophosphoric acid (TPA) co-delivery Glipizide (GLP) Metformin Hydrochloride (MTF) as well characterization using various techniques. An vitro release study was carried out at two different pHs (pH 1.2 pH 7.4) 37 °C under stirring conditions further supported an dissolution USP Type II apparatus. obtained results were compared that marketed available formulation, Glirum-MF, designed showed controlled both drugs comparison conventional drug. Additionally, considering anticancer properties drugs, MTT assay indicated carrier non-toxic while loaded shows apoptosis against HepG2 cells.
Language: Английский
Citations
0
Cells, Journal Year: 2025, Volume and Issue: 14(8), P. 564 - 564
Published: April 9, 2025
Cancer risk increases by 25 to 250% not only in dysmetabolic obese or overweight people with overt type 2 diabetes but also individuals intermediate hyperglycemia (pre-diabetes), especially pronounced of pancreatic hepatocellular cancer and obesity-related cancers, e.g., colorectal kidney bladder men, endometrial breast cancers women. may often be present before upon the diagnosis diabetes, as there is a common pathogenetic dysmetabolic-inflammatory background insulin resistance for developing cardiorenal disease, parallel. The mechanisms involved relate hyperinsulinemia potential carcinogenic priming event ectopic visceral, hepatic, pancreatic, renal fat accumulation that subsequently fuel inflammation lipo-oncogenic signals, causing mitochondrial oxidative stress deregulation. Moreover, foster mitogenic MAP kinase-related signaling, which can occur via IGF1 receptors due increased free levels obesity. Weight reduction 10% more pre-diabetes, through intensive lifestyle intervention bariatric (=metabolic) surgery treatment GLP-1 receptor agonists metformin, associated significantly lower incidence "diabesity"-associated cancers. In conclusion, seems huge utility adopting new "Cardio-Renal-Metabolic-Cancer Syndrome" approach, looking at time addition proactively screening undiagnosed dysglycemia.
Language: Английский
Citations
0
Biomolecules, Journal Year: 2024, Volume and Issue: 14(11), P. 1479 - 1479
Published: Nov. 20, 2024
Diabetes mellitus (DM) is a significant risk factor for various cancers, with the impact of anti-diabetic therapies on cancer progression differing across malignancies. Among these therapies, metformin has gained attention its potential anti-cancer effects, primarily through modulation AMP-activated protein kinase/mammalian target rapamycin (AMPK/mTOR) pathway and induction autophagy. Beyond metformin, other conventional treatments, such as insulin, sulfonylureas (SUs), pioglitazone, dipeptidyl peptidase-4 (DPP-4) inhibitors, have also been examined their roles in biology, though findings are often inconclusive. More recently, novel medications, like glucagon-like peptide-1 (GLP-1) receptor agonists, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) sodium-glucose co-transporter-2 (SGLT-2) revolutionized DM management by not only improving glycemic control but delivering substantial cardiovascular renal benefits. Given diverse metabolic including anti-obesogenic properties, agents now under meticulous investigation influence tumorigenesis advancement. This review aims to offer comprehensive exploration evolving landscape glucose-lowering treatments implications biology. It critically evaluates experimental evidence surrounding molecular mechanisms which medications may modulate oncogenic signaling pathways reshape tumor microenvironment (TME). Furthermore, it assesses translational research clinical trials gauge practical relevance real-world settings. Finally, explores adjuncts treatment, particularly enhancing efficacy chemotherapy, minimizing toxicity, addressing resistance within framework immunotherapy.
Language: Английский
Citations
1
LabMed discovery., Journal Year: 2024, Volume and Issue: unknown, P. 100022 - 100022
Published: Nov. 1, 2024
Language: Английский
Citations
1
Oral Oncology, Journal Year: 2024, Volume and Issue: 161, P. 107143 - 107143
Published: Dec. 17, 2024
Language: Английский
Citations
1